Recombinant Cynomolgus B7-H7/HHLA2 Fc Chimera Protein, CF

Recombinant Cynomolgus Monkey B7-H7/HHLA2 Fc Chimera (Catalog #10108-B7) inhibits anti-CD3 antibody induced IL-2 secretion in human Tlymphocytes. The ED50 for this effect is 1‑6 μg/mL.

1 μg/lane of Recombinant Cynomolgus Monkey B7-H7/HHLA2 Fc Chimera (Catalog # 10108-B7) wasresolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions andvisualized by silver staining, showing bands at 92-109 kDa and 180-220 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus B7-H7/HHLA2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED₅₀ for this effect is 1-6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey B7-H7/HHLA2 protein
  

  Cynomolgus Monkey B7-H7 (Ile21-Asn345) Accession # XP_005548285	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005548285
• N-terminal Sequence: Ile21
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 64 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 92-109 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Citric Acid and NaCl with Trehalose.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus B7-H7/HHLA2 Fc Chimera Protein, CF

• B7H7
• B7-H7
• HERV-H LTR-associating 2
• HERV-H LTR-associating protein 2
• HHLA2
• Human endogenous retrovirus-H long terminal repeat-associating protein 2

Background

B7-H7, also known as HHLA2 (HERV-H LTR-associating protein 2), is a member of the B7 family of immune regulatory proteins (1, 2). The mature human B7-H7 protein consists of a 322 amino acid (aa) extracellular domain (ECD) with three immunoglobulin-like domains, a 21 aa transmembrane segment, and a 49 aa cytoplasmic domain (3-5). Within the ECD, cynomolgus B7-H7 shares 90% aa sequence identity with human B7-H7. It is constitutively expressed on monocytes and is up-regulated by LPS and IFN-gamma stimulation. It is expressed on LPS/IFN-gamma treated B cells but not on resting B cells (5). B7-H7 binds to cell surface determinants on resting and mature T cells, B cells, and monocytes as well as on immature and mature dendritic cells (5). The receptor TMIGD2, commonly found in endothelial and epithelial cells, has also been identified as one of the receptors for B7-H7 (6). Soluble B7-H7 inhibits the proliferation of activated CD4⁺ and CD8⁺ T cells and their production of IFN-gamma, TNF-alpha, IL-5, IL-10, IL-13, IL-17A, and IL-22 (5).

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.
2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
3. Mager, D.L. et al. (1999) Genomics 59:255.
4. Flajnik, M.M. et al. (2012) Immunogenetics 64:571.
5. Zhao, R. et al. (2013) Proc. Natl. Acad. Sci. USA 110:9879.
6. Janakiram, M. et al. (2015) OncoImmunology 4:e1026534-1

Bioinformatics

• Uniprot:
  • XP_005548285()